Caitong International Asset Management’s Lucid Diagnostics LUCD Stock Holding History

Caitong International Asset Management’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3	Buy	+3	New	+$4	﹤0.01%	2384

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Caitong International Asset Management's LUCD Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 3 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #2384 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Caitong International Asset Management held 3 shares of Lucid Diagnostics worth $3 as of Q1 2026.
Lucid Diagnostics was a new Caitong International Asset Management position in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2384 holding.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.